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ABSTRACT 41 
Background: In small studies and cases series, a history of tuberculosis has been associated 42 
with both airflow obstruction, which is characteristic of chronic obstructive pulmonary 43 
disease, and restrictive patterns on spirometry. 44 
Objective: To assess the association between a history of tuberculosis and airflow 45 
obstruction and spirometric abnormalities in adults. 46 
Methods: The study was performed in adults, aged 40 and above, who took part in the 47 
multicentre cross-sectional, general population-based, Burden of Obstructive Lung Disease 48 
study, had provided acceptable post-bronchodilator spirometry measurements and 49 
information on a history of tuberculosis. 50 
The associations between a history of tuberculosis and airflow obstruction and spirometric 51 
restriction were assessed within each participating centre, and estimates combined using 52 
meta-analysis. These estimates were stratified by high and low/middle income countries, 53 
according to gross national income. 54 
Results: A self-reported history of tuberculosis was associated with airflow obstruction 55 
(adjusted odds ratio = 2.51, 95% confidence interval 1.83-3.42) and spirometric restriction 56 
(adjusted odds ratio = 2.13, 95% confidence interval 1.42-3.19). 57 
Conclusion: A history of tuberculosis was associated with both airflow obstruction and 58 
spirometric restriction, and should be considered as a potentially important cause of 59 
obstructive disease and low lung function, particularly where tuberculosis is common. 60 
  61 
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Introduction 62 
In 2012, there were an estimated 8.6 million new cases of tuberculosis worldwide (1) , with 63 
South-East Asia, Western Pacific Regions, and Africa accounting for more than 75% of the 64 
toll. More than 30% of the world population may have latent tuberculosis, but only 5-20% of 65 
them develop active tuberculosis at some point in their lifetime (1, 2). Those who survive it 66 
usually show post-treatment sequelae in the lung that may contribute to reduced quality of 67 
life and disability (3-5).  68 
Airflow obstruction is characteristic of chronic obstructive pulmonary disease (COPD), and 69 
its main risk factor is tobacco smoking (6, 7). However, more than 20% of patients satisfying 70 
the criteria for COPD do not have a history of tobacco smoking (8, 9). Among other potential 71 
risk factors, a history of tuberculosis has been suggested by several studies as a strong 72 
predictor of chronic airflow obstruction that could explain COPD among non-smokers (9-11). 73 
With some exceptions, most of these studies were small (n < 1000), not population-based (i.e. 74 
participants not randomly selected from general population) and limited to a single centre or 75 
country, and several used pre-bronchodilator instead of post-bronchodilator spirometric 76 
measurements (11). 77 
Spirometric restriction is characteristic of restrictive lung diseases and has been reported as a 78 
consequence of tuberculosis since the late 1910s (12, 13). More recent epidemiological 79 
studies with South African miners and hospital-based cases have suggested that a history of 80 
tuberculosis and increasing number of events of this disease may lead to a deficit in lung 81 
function (14-18). However, population data to support the association between a history of 82 
tuberculosis and spirometric restriction is lacking. 83 
The aim of the present analysis was to assess the association of airflow obstruction and 84 
spirometric restriction with a history of tuberculosis in the large international, population-85 
based, Burden of Obstructive Lung Disease (BOLD) study. 86 
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 87 
Methods 88 
Participants 89 
The design and rationale for the BOLD study have been reported elsewhere (19). Non-90 
institutionalised adults aged 40 years and older were sampled and invited to take part in the 91 
study. Sampling plans designed to randomly recruit a representative sample of the population 92 
at all study sites were used.  93 
Of the 21,962 participants who responded to the core questionnaire, 18,669 had acceptable 94 
post-bronchodilator spirometry, and of these 18,664 answered a question on history of 95 
tuberculosis. Data were available from 27 sites, but Australia (Sydney), India (Mumbai, 96 
Srinagar), Malaysia (Penang), Nigeria (Ife), Norway (Bergen), Tunisia (Sousse), Turkey 97 
(Adana), which each contained less than five participants with history of tuberculosis, were 98 
excluded; therefore the present study population consists of 14,050 participants from 19 sites. 99 
The countries and sites represented in this analysis are: Albania (Tirana), Algeria (Annaba), 100 
Austria (Salzburg), Canada (Vancouver), China (Guangzhou), England (London), Estonia 101 
(Tartu), Germany (Hannover), Iceland (Reykjavik), India (Pune), Morocco (Fes), Netherlands 102 
(Maastricht), Philippines (Manila, Nampicuan & Talugtug), Poland (Krakow), Portugal 103 
(Lisbon), South Africa (Cape Town), Sweden (Uppsala), and USA (Lexington). All sites 104 
received approval from their local ethics committee, and participants provided written 105 
informed consent. 106 
 107 
History of tuberculosis 108 
Face-to-face interviews were conducted by trained and certified staff in the native language 109 
of the participant in order to collect information on respiratory symptoms, health status, and 110 
exposure to risk factors. A history of tuberculosis was defined as a positive answer to the 111 
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question: “Has a doctor or other health care provider ever told you that you have 112 
tuberculosis?” Participants who were on treatment for tuberculosis at the time of the study 113 
were excluded from participation. 114 
 115 
Outcome measures 116 
Lung function, including forced expiratory volume in one second (FEV1) and forced vital 117 
capacity (FVC), was measured using the ndd EasyOne Spirometer (ndd Medizintechnik AG, 118 
Zurich, Switzerland), before and 15 minutes after administration of salbutamol (200 μg) from 119 
a metered dose inhaler through a spacer. The BOLD Pulmonary Function Reading Centre 120 
reviewed each spirogram and assigned them a quality score based on acceptability and 121 
reproducibility criteria from the American Thoracic Society (ATS) and European Respiratory 122 
Society (ERS) (20). Spirometry technicians at BOLD sites were certified before data 123 
collection, received regular feedback on quality, and were required to maintain a pre-124 
specified quality standard. 125 
Outcome measures were: i) airflow obstruction, defined as a post-bronchodilator FEV1/FVC 126 
ratio below the low limit of normal (LLN) for age and sex (21), based on reference equations 127 
for Caucasians derived from the third US National Health and Nutrition Examination Survey 128 
(NHANES) (22); and ii) spirometric restriction, defined as a post-bronchodilator FVC below 129 
the LLN for height, age and sex, based on the same reference population. 130 
 131 
Statistical analysis 132 
To assess the association of airflow obstruction and spirometric restriction with history of 133 
tuberculosis, multivariable logistic regression models were fitted and adjusted for age (years), 134 
sex, body mass index (underweight: <18.5, normal: 18.5 to <24, overweight: 24 to <30, 135 
obese: 30+ kg/m2), and pack-years of smoking. Additional variables were considered as 136 
7 
 
potential confounders: education (years of schooling complete), passive smoking (yes, no), 137 
and cumulative exposure to dust in the workplace (years). The association with a history of 138 
tuberculosis was estimated for each site using probability weights to allow for the sampling 139 
design at each site and then combined in a random effects meta-analysis. The meta-analyses 140 
were stratified by gross national income, i.e. high vs low/middle income countries. The level 141 
of heterogeneity was summarised using the I2 statistic. We also regressed FEV1/FVC and 142 
FVC (L) as continuous variables against the same independent variables as above. Sensitivity 143 
analyses were conducted excluding participants presenting with both airflow obstruction and 144 
spirometric restriction. In another set of sensitivity analyses, the association of a history of 145 
tuberculosis with airflow obstruction, spirometric restriction, FEV1/FVC, and FVC was 146 
assessed omitting all sites with a cooperation rate below 60%. All analyses were conducted 147 
using Stata/IC V.12.1 (StataCorp LP, College Station, TX, USA). 148 
 149 
Results 150 
The characteristics of the 14,050 participants with acceptable post-bronchodilator spirometry, 151 
who responded to the core questionnaire and answered the question on history of tuberculosis 152 
are presented, by site, in table 1. There were slightly more females than males, and the overall 153 
age ranged from 52.3 to 59.6 across sites. Cumulative smoking exposure, i.e. pack-years, and 154 
passive smoking varied widely across sites. The prevalence of a history of tuberculosis [0.7% 155 
in Albania (Tirana) to 15.4% in South Africa (Cape Town)] as well as the prevalence of 156 
airflow obstruction [6.1% in Estonia (Tartu) and India (Pune) to 19.5% in South Africa (Cape 157 
Town)] and spirometric restriction [8.5% in Canada (Vancouver) and Estonia (Tartu) to 158 
66.1% in India (Pune)] also varied across sites (Tables 1 and 2). 159 
The unadjusted odds ratio (OR), and 95% confidence interval (CI), for the association 160 
between airflow obstruction and history of tuberculosis was 3.33 (2.54-4.37). Figure 1 shows 161 
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adjusted ORs, and 95% CIs, for this association, by gross national income group and site. 162 
Overall, the risk of airflow obstruction in people with a history of tuberculosis was more than 163 
twice as much as that of people without such a history (aOR = 2.51, 95% CI 1.83-3.42). This 164 
association was stronger in low/middle income sites (aOR = 3.11, 95% CI 2.30-4.21) and 165 
showed no evidence of heterogeneity (I2 = 0%, P = 0.55). 166 
The unadjusted OR, and 95% CI, for the association between spirometric restriction and 167 
history of tuberculosis was 2.02 (1.42-2.86). Figure 2 shows adjusted ORs, and 95% CIs, by 168 
gross national income group and site for this association. The overall pooled aOR was 2.13 169 
(95% CI 1.42-3.19), and significant heterogeneity across sites was recorded (I2 = 62.4%, P < 170 
0.001). In high income sites there was no evidence of heterogeneity (I2 = 0%; p=0.72) but the 171 
risk was low and not significant (aOR = 1.43, 95% CI 0.93, 2.18). In low income countries, 172 
although the risk was higher and significant (aOR = 3.19; 95% CI 1.70, 5.99) there was a 173 
marked and unexplained heterogeneity in the risk estimates (I2 = 79.1%; p<0.001). 174 
In both figures 1 and 2, ORs are adjusted for age, sex, body mass index, and pack-years. 175 
Adjustment for education, passive smoking, and cumulative exposure to dust in the 176 
workplace did not materially change the estimates for the effect of tuberculosis. Poland 177 
(Krakow) was excluded from the analyses due to insufficient number of participants with 178 
both history of tuberculosis and either airflow obstruction (n = 0) or spirometric restriction (n 179 
= 2). 180 
A history of tuberculosis was also associated with both decreased FEV1/FVC (beta = -3.43, 181 
95% CI -5.05 to -1.80; I2 = 65.3%, P < 0.001) and decreased FVC (beta = -0.15, 95% CI -182 
0.23 to -0.06; I2 = 48.6%, P = 0.01) (supplementary figures 1 and 2). 183 
Sensitivity analyses, excluding 482 participants who had both FEV1/FVC<LLN and 184 
FVC<LLN, showed that the magnitude of the effects of tuberculosis reduced slightly but 185 
remained statistically significant (aOR for airflow obstruction = 2.13, 95% CI 1.40-3.23; aOR 186 
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for spirometric restriction = 2.11, 95% CI 1.31-3.38), suggesting that these effects are largely 187 
independent of each other. 188 
The omission of sites with a cooperation rate below 60% did not materially change the results 189 
(supplementary figures 3-6). 190 
 191 
Discussion 192 
In this population-based study of adults aged 40 years and over, a history of tuberculosis was 193 
associated with increased risk of airflow obstruction. A history of tuberculosis was also 194 
associated with spirometric restriction, but mainly in sites in low/middle income countries. 195 
The strengths of the present study are: i) its large population-based sample and the inclusion 196 
of a great number of sites; ii) the use of a standardised questionnaire for collection of data on 197 
risk factors and protocol for spirometry across sites; and iii) the use of post- instead of pre-198 
bronchodilator spirometric measurements. The most convincing effect relates to obstruction 199 
in low/middle income countries where the odds ratio was high (OR = 3.11) and the results 200 
were consistent between sites (I2 = 0%). 201 
Our study also has some limitations. One is its cross-sectional nature, which impedes us from 202 
drawing conclusions in terms of temporality and makes us consider the possibility of reverse 203 
causation. Tuberculosis is more common in people with some restrictive diseases such as 204 
silicosis, but these are relatively very rare. Tuberculosis may also be reactivated in those who 205 
take corticosteroids, and particularly inhaled corticosteroid treatment recommended in 206 
chronic airway disease. However, their use is rare in this population and even rarer in the 207 
low/middle income countries where the association between tuberculosis and airflow 208 
obstruction is most pronounced. In some sites response rates were lower than desirable, but 209 
when we omitted all sites with a cooperation rate below 60% results did not materially 210 
change. Another limitation is the use of data on a self-reported history of tuberculosis, which 211 
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may suffer from under-reporting due to stigmatisation of the diagnosis. However, differential 212 
under-reporting due to stigmatisation between people with and without airflow obstruction or 213 
spirometric restriction seems unlikely. It is also possible that several participants have 214 
suffered from tuberculosis and healed without any treatment and thus tuberculosis infection 215 
may be underestimated. However, in a study in China, the magnitude of the association of 216 
airflow obstruction with tuberculosis was similar between self-reports and radiological 217 
confirmation (23). According to ATS/ERS (24), pulmonary restriction is defined by a total 218 
lung capacity (TLC) less than the fifth percentile of the predicted value. This implies 219 
measuring TLC by plethysmography or helium dilution, which is unrealistic in large-scale 220 
epidemiological studies, such as this, and especially at centres in low/middle income 221 
countries. We are mindful that our choice of FVC as a surrogate of TLC may lead to false 222 
positive findings in those with increased residual volumes, but outside the clinical 223 
environment the prevalence of this is very low. We are also aware that the use of the 224 
NHANES reference equations in our spirometry measurements may overemphasize lung 225 
function abnormality in some study sites, but the effect of this is unlikely to be differential as 226 
the analyses were done within each site (the sites are ethnically fairly homogeneous) and only 227 
then were meta-analysed. In addition, the results from the binary outcomes (FEV1/FVC < 228 
LLN, and FVC < LLN) are supported by those of the continuous outcomes (FEV1/FVC, and 229 
FVC), which are independent of reference equations. 230 
Our findings add to existing knowledge and support the majority of previous smaller studies 231 
that have reported an association between airflow obstruction and a history of tuberculosis 232 
(10, 11, 25). We also confirm findings from the few occupational and small hospital-based 233 
studies that have observed a decline in lung function associated with both history of and 234 
radiographically-confirmed tuberculosis (14-18). 235 
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Although it is widely accepted that tuberculosis and the healing process the lung undergoes 236 
during and after treatment can cause scarring that leads to loss of parenchymal tissue and 237 
restrictive spirometry, it is not clear what mechanisms explain airflow obstruction associated 238 
with tuberculosis. The finding that tuberculosis is associated with airflow obstruction, and not 239 
only with spirometric restriction, suggests that this is not solely the result of parenchymal 240 
scarring. One possibility is that this is caused by bronchiectasis and bronchial stenosis, which 241 
can occur as a result of tuberculosis (26). Another possibility is that this is caused by a 242 
dysregulation of macrophages arising from latent intracellular infection (27). Macrophages in 243 
the lung act primarily to kill bacteria or to facilitate wound healing and resolution (28), and it 244 
is widely accepted that they play a central role in the remodelling that causes chronic airflow 245 
obstruction. It is possible that latent mycobacteria in lung macrophages could lead to 246 
maintenance of inflammation in the lung and more aggressive remodelling of the airways (28, 247 
29). 248 
In summary, a history of tuberculosis was associated with both airflow obstruction and 249 
spirometric restriction. Nevertheless, large longitudinal studies with post-bronchodilator 250 
spirometry are recommended to confirm or refute these findings. With the continuing spread 251 
of tuberculosis in developing countries, an increasing incidence of multi-drug resistant 252 
disease, and an aging world population, it is important to improve our understanding of the 253 
mechanisms that link tuberculosis to airflow obstruction and COPD, and to devise effective 254 
strategies to limit this problem. 255 
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Tables’ legends 463 
Table 1. Characteristics of participants from 19 sites of the Burden of Obstructive Lung 464 
Disease (BOLD) study with good quality spirometry and data on history of tuberculosis (at 465 
least 5 cases). 466 
 467 
Table 2. Estimated population prevalence of airflow obstruction and spirometric restriction in 468 
19 sites of the Burden of Obstructive Lung Disease (BOLD) study with good quality 469 
spirometry and data on history of tuberculosis (at least 5 cases). 470 
 471 
Figures’ legends 472 
Figure 1. Odds ratios of airflow obstruction for a history of tuberculosis, by gross national 473 
income group (low/middle vs high) and site. All models were adjusted for age, sex, body 474 
mass index, and pack-years of smoking. 475 
 476 
Figure 2. Odds ratios of spirometric restriction for a history of tuberculosis, by gross national 477 
income group (low/middle vs high) and site. All models were adjusted for age, sex, body 478 
mass index, and pack-years of smoking. 479 
 480 
Supplementary figure 1. Change in FEV1/FVC due to a history of tuberculosis, by gross 481 
national income group (low/middle vs high) and site. All models were adjusted for age, sex, 482 
body mass index, and pack-years of smoking. 483 
 484 
Supplementary figure 2. Change in FVC due to a history of tuberculosis, by gross national 485 
income group (low/middle vs high) and site. All models were adjusted for age, sex, body 486 
mass index, and pack-years of smoking. 487 
22 
 
 488 
Supplementary figure 3. Odds ratios of airflow obstruction for a history of tuberculosis, by 489 
gross national income group (low/middle vs high) and site, omitting sites with a cooperation 490 
rate below 60%. All models were adjusted for age, sex, body mass index, and pack-years of 491 
smoking. 492 
 493 
Supplementary figure 4. Odds ratios of spirometric restriction for a history of tuberculosis, 494 
by gross national income group (low/middle vs high) and site, omitting sites with a 495 
cooperation rate below 60%. All models were adjusted for age, sex, body mass index, and 496 
pack-years of smoking. 497 
 498 
Supplementary figure 5. Change in FEV1/FVC due to a history of tuberculosis, by gross 499 
national income group (low/middle vs high) and site, omitting sites with a cooperation rate 500 
below 60%. All models were adjusted for age, sex, body mass index, and pack-years of 501 
smoking. 502 
 503 
Supplementary figure 6. Change in FVC due to a history of tuberculosis, by gross national 504 
income group (low/middle vs high) and site, omitting sites with a cooperation rate below 505 
60%. All models were adjusted for age, sex, body mass index, and pack-years of smoking. 506 
  507 
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Table 1. Characteristics of participants from 19 sites of the Burden of Obstructive Lung Disease (BOLD) study with good quality spirometry and data on history of 
tuberculosis (at least 5 cases). 
 
A
lb
an
ia
 
(T
ir
an
a)
 
A
lg
er
ia
 
(A
n
n
ab
a)
 
A
u
st
ri
a 
(S
al
zb
u
rg
) 
C
an
ad
a 
(V
an
co
u
v
er
) 
C
h
in
a 
(G
u
an
g
zh
o
u
) 
E
n
g
la
n
d
 
(L
o
n
d
o
n
) 
E
st
o
n
ia
 
(T
ar
tu
) 
G
er
m
an
y
 
(H
an
n
o
v
er
) 
Ic
el
an
d
 
(R
ey
k
ja
v
ik
) 
In
d
ia
 
(P
u
n
e)
 
M
o
ro
cc
o
 
(F
es
) 
N
et
h
er
la
n
d
s 
(M
aa
st
ri
ch
t)
 
P
h
il
ip
p
in
es
 
(M
an
il
a)
 
P
h
il
ip
p
in
es
 
(N
am
p
ic
u
an
 
&
 T
al
u
g
tu
g
) 
P
o
la
n
d
 
(K
ra
k
o
w
) 
P
o
rt
u
g
al
 
(L
is
b
o
n
) 
S
o
u
th
 A
fr
ic
a 
(C
ap
e 
T
o
w
n
) 
S
w
ed
en
 
(U
p
p
sa
la
) 
U
S
A
 
(L
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N 939 890 1253 827 461 675 613 680 757 845 768 590 892 722 526 711 846 547 508 
Age (yrs), 
mean (SD) 
55.4 
(11.7) 
53.5 
(10.9) 
59.2 
(12.2) 
56.8 
(12.7) 
54.0 
(10.6) 
58.0 
(12.4) 
59.6 
(12.2) 
57.7 
(11.1) 
57.0 
(12.0) 
52.3 
(10.0) 
54.2 
(11.9) 
58.5 
(12.0) 
52.7 
(11.1) 
54.2 
(10.6) 
56.2 
(11.8) 
58.5 
(12.0) 
53.5 
(10.5) 
58.9 
(11.4) 
57.0 
(11.6) 
Males (%) 48.9 49.9 46.1 47.3 52.0 46.2 39.1 45.4 51.3 59.8 52.2 46.8 47.5 49.4 49.6 45.3 43.8 47.1 46.4 
BMI 
(kg/m2), 
mean (SD)* 
28.0 
(4.6) 
28.2 
(5.6) 
26.4 
(4.3) 
26.7 
(5.1) 
23.3 
(3.2) 
27.3 
(5.2) 
28.4 
(5.4) 
27.1 
(4.6) 
27.9 
(5.0) 
22.1 
(3.9) 
27.5 
(5.2) 
27.5 
(4.6) 
24.4 
(4.7) 
21.6 
(4.1) 
27.8 
(4.7) 
27.9 
(4.7) 
27.5 
(7.3) 
26.9 
(4.4) 
30.6 
(6.5) 
Pack-years, 
mean 
(SD)** 
11.5 
(19.3) 
10.4 
(18.3) 
12.7 
(20.7) 
12.1 
(21.4) 
11.8 
(17.7) 
17.5 
(27.4) 
7.4 
(13.0) 
14.6 
(20.4) 
12.9 
(24.9) 
0.7 
(3.6) 
6.6 
(14.9) 
14.5 
(19.0) 
10.6 
(18.6) 
12.9 
(18.4) 
15.8 
(25.5) 
13.1 
(25.0) 
11.9 
(16.1) 
10.4 
(16.2) 
24.4 
(34.7) 
Passive 
smoking 
(%) 
37.4 10.9 21.8 5.7 23.6 16.6 15.6 18.6 16.8 11.1 11.4 17.7 48.8 47.3 39.3 18.7 50.6 5.8 29.6 
Education 
(yrs), mean 
(SD)† 
10.0 
(4.6) 
7.7 
(5.4) 
9.8 
(2.2) 
15.4 
(3.4) 
8.4 
(3.9) 
13.6 
(3.6) 
13.5 
(3.8) 
10.3 
(2.2) 
13.2 
(4.4) 
4.3 
(4.3) 
4.2 
(5.3) 
14.9 
(5.1) 
9.4 
(3.6) 
7.8 
(3.6) 
10.4 
(3.4) 
8.5 
(4.9) 
7.8 
(3.3) 
12.8 
(4.0) 
12.8 
(3.3) 
Cumulative 
exposure to 
dust in 
workplace 
(yrs), mean 
(SD)‡ 
15.0 
(14.1) 
5.6 
(10.3) 
5.2 
(11.7) 
3.1 
(7.5) 
6.9 
(11.6) 
4.0 
(9.7) 
5.0 
(10.1) 
3.3 
(8.7) 
4.2 
(9.6) 
1.8 
(5.5) 
8.5 
(12.8) 
3.3 
(8.8) 
7.1 
(10.8) 
6.1 
(11.8) 
10.5 
(13.4) 
10.6 
(14.3) 
6.8 
(10.3) 
5.5 
(11.3) 
8.3 
(12.1) 
PB-FEV1 
(l/s), mean 
(SD) 
2.8 
(0.8) 
2.7 
(0.8) 
2.9 
(0.9) 
3.0 
(0.9) 
2.4 
(0.7) 
2.7 
(0.9) 
2.9 
(0.9) 
3.0 
(0.8) 
3.0 
(0.9) 
2.2 
(0.6) 
2.7 
(0.7) 
2.9 
(0.9) 
2.1 
(0.6) 
2.1 
(0.7) 
2.9 
(0.9) 
2.7 
(0.9) 
2.3 
(0.7) 
3.0 
(0.9) 
2.7 
(0.9) 
PB-FVC (l), 
mean (SD) 
3.5 
(0.9) 
3.4 
(0.9) 
3.9 
(1.0) 
4.0 
(1.1) 
3.1 
(0.8) 
3.6 
(1.1) 
3.8 
(1.1) 
3.9 
(1.0) 
4.0 
(1.0) 
2.7 
(0.7) 
3.4 
(0.9) 
3.8 
(1.1) 
2.6 
(0.7) 
2.7 
(0.8) 
3.8 
(1.0) 
3.4 
(1.1) 
3.0 
(0.9) 
3.9 
(1.1) 
3.5 
(1.1) 
History of 
tuberculosis 
(%) 
0.7 2.2 2.9 3.2 3.5 2.1 7.0 3.6 4.0 0.9 1.4 1.4 10.8 3.6 2.8 4.5 15.4 1.1 1.9 
24 
 
SD, standard deviation. BMI, body mass index. PB-FEV1, post-bronchodilator forced expiratory volume in 1 second. PB-FVC, post-bronchodilator forced vital 
capacity. Education, years of schooling complete. *Missing: 3 in Poland (Krakow); 2 in South Africa (Cape Town); and 1 in USA (Lexington). **Missing: 7 in 
Philippines (Manila); 3 in Philippines (Nampicuan & Talugtug) and Poland (Krakow); 2 in Canada (Vancouver), South Africa (Cape Town) and Netherlands 
(Maasstricht); and 1 in Iceland (Reykjavik), Morocco (Fes) and Sweden (Uppsala). †Missing: 7 in Philippines (Nampicuan & Talugtug); 5 in England (London); and 1 
in Estonia (Tartu), Morocco (Fes), Portugal (Lisbon) and South Africa (Cape Town). ‡Missing: 4 in Netherlands (Maasstricht). 
 
Table 2. Estimated population prevalence of airflow obstruction and spirometric restriction in 19 sites of the Burden of Obstructive Lung Disease (BOLD) study with 
good quality spirometry and data on history of tuberculosis (at least 5 cases). 
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N 939 890 1253 827 461 675 613 680 757 845 768 590 892 722 526 711 846 547 508 
Airflow 
obstruction 
(%) 
8.9 6.4 17.4 13.5 7.6 17.6 6.1 8.2 11.3 6.1 8.9 18.8 9.4 15.2 13.5 8.3 19.5 9.6 14.4 
Spirometric 
restriction 
(%) 
16.1 26.5 9.3 8.5 29.9 17.8 8.5 9.0 12.5 66.1 19.3 10.1 62.7 56.7 10.1 10.7 46.7 10.2 26.2 
Response rate 
(%)* 
82.3 94.6 65.0 26.0 87.0 17.0 49.0 59.0 81.0 97.0 98.0 48.0 58.0 85.5 78.0 10.0 63.0 61.0 14.0 
Cooperation 
rate 
(%)** 
84.0 94.6 67.0 51.0 87.0 37.0 70.0 61.0 84.0 97.0 98.0 55.0 58.0 86.2 79.0 27.0 68.0 63.0 27.0 
Airflow obstruction, FEV1/FVC < LLN. Spirometric restriction, FVC < LLN. *Denominator comprises people of unknown eligibility status who could not be 
contacted. Only known participants considered ineligible were excluded. **Denominator comprises only participants who were contacted and eligible. 
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